110 results about "Neurodevelopmental disorder" patented technology

The present disclosure provides methods of treating a neurodevelopmental disorder (NDD) in a subject by administering a therapeutically effective amount of N-acetyl leucine.

The present invention is directed to genetic manipulation of neural cells in the gyrencephalic fetal brain for developing treatment strategies for various neurodevelopmental disorders.

Provided are apparatuses, a non-transitory computer-readable medium or media, for predicting of neurodevelopmental disorder using a fundus image of a subject. In certain aspects, disclosed a method including the steps of: receiving the fundus image; processing the fundus image to classify one or more features contained in the fundus image using a machine learning model; and predicting, based on a classification, whether the fundus image is indicative of presence of neurodevelopmental disorder in the subject, wherein the machine learning model has been trained on stored fundus images obtained from at least two group of subjects who have previously been diagnosed as having the neurodevelopmental disorder, the machine learning model is trained by processes comprising; extracting a first embedding vector and a second embedding vector from a first fundus image and a second fundus image, respectively; and maximizing a similarity between the first embedding vector and the second embedding vector.

Embodiments of the invention provide a solution for ameliorating microbiome effects on neurodevelopment by developing a probiotic composition for consumption by a female during gestation. In certain aspects the probiotic is a multi-strain probiotic cocktail consisting of immunomodulatory taxa and administered females during pregnancy and lactation.

The invention discloses a neural development disorder co-disease identification system based on a residual image neural network. Belongs to the technical field of neurodevelopment disorder co-disease recognition, and particularly relates to the technical field of co-disease recognition based on a neural network. The system comprises a data acquisition module for acquiring a resting-state fMRI image; the data preprocessing module is used for extracting standardized time sequences of 116 brain regions of the set resting state fMRI image; the multi-band division and feature extraction module is used for performing frequency band filtering on the standardized time sequence of each brain region to obtain a time sequence after each frequency band filtering; in each frequency band, constructing a binary topological matrix based on the PLV matrix and calculating a PLV feature vector based on the PLV matrix; the neurodevelopmental disorder co-disease recognition module is used for analyzing the brain function connection diagram through a residual image neural network model to obtain diagnostic information of neurodevelopmental disorder co-diseases; and the interpretable output module is used for outputting an abnormal brain region by taking the amplitude low-frequency fluctuation as a reference index.

The invention belongs to the technical field of nutritional compositions, and particularly relates to a composition, a preparation method thereof and application of the composition in protecting brain health. The composition provided by the invention is prepared from docosahexaenoic acid, 3-sialic acid lactose and phosphatidylserine. The composition is clear in sleep improvement effect, can effectively solve the problem of sleep maintenance caused by sleep deprivation, has the effects of protecting neural functions, improving memory and relieving anxiety from multiple dimensions, and can repair brain tissue damage and protect brain health. Based on the composition, products for assisting in improving memory, preventing and treating insomnia and anxiety, regulating neurodevelopmental disorders, protecting brain health and improving concentration can be developed, the health requirements of different people are comprehensively met, and the application value is high.

The present invention relates to a system for aiding the diagnosis of neurodevelopmental disorders and / or associated mental health disorders in a child or teenager user, the system comprising: an interface module configured to present an interactive program to the user, preferably the program being a game; the acquisition module is configured to receive a plurality of time biological characteristic signals generated by interaction of a user and the interface module at the same time when the user interacts with the program; an extraction module configured to extract or calculate, based on each temporal feature signal, at least one correlation feature for evaluating at least one symptom related to at least one neurodevelopmental disorder or associated mental health disorder of the child or teenager; and a classification module configured to assign one or more scores related to one or more symptoms to the user based on the features extracted or calculated by the extraction module and a machine learning model previously trained based on a set of annotation data collected from the child user, the one or more symptoms are associated with one or more neurodevelopmental disorders or associated mental health disorders.

The present invention relates to novel phosphate ester compounds of formula I for use in the treatment of central nervous system (CNS) diseases. Furthermore, the present invention provides an improved process for obtaining the compound of formula (I) in high yield and high purity. The novel phosphate ester compounds of formula-I are useful in the treatment of neurological, neuropsychiatric, metabolic and neurodevelopmental disorders.

Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

This disclosure belongs to the field of medical testing technology, and specifically relates to a classification, diagnostic, and prediction method, system, and electronic device for congenital neurodevelopmental disorders. Addressing the clinical diagnostic challenges of congenital neurodevelopmental disorders, this disclosure establishes for the first time a classification, diagnostic, and prediction method for congenital neurodevelopmental disorders based on whole-genome methylation signatures and customized SVM machine learning. This method achieves one-stop differential diagnosis across multiple mechanisms and diseases, filling a gap in existing technologies and providing a novel and efficient solution for the accurate diagnosis of congenital neurodevelopmental disorders.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

The invention provides a network science-based method for evaluating a herbicide neurodevelopmental toxicity risk. The herbicide which is widely used and is detected at high frequency in the environment is collected; acquiring a herbicide target and risk genes of neurodevelopment disorder related diseases; constructing a herbicide target network and a disease module; analyzing the neuro-developmental toxicity risk of the herbicide by network proximity; constructing an overlapping network of a herbicide target network and a disease module; screening core pathogenic genes based on multiple network topology algorithms and carrying out gene enrichment analysis; the toxicity risk is evaluated from the molecular level, and the high-risk herbicide variety is effectively discriminated. And a neuro-developmental toxic molecular mechanism of the herbicide is analyzed based on a network analysis system, so that a new framework from risk assessment to mechanism analysis is constructed for toxicity research of environmental chemicals.

To provide an execution function evaluation device capable of evaluating an execution function related to a symptom of a neurodevelopmental disease group.SOLUTION: An execution function evaluation device 1 is an evaluation device for an execution function related to a symptom of a neurodevelopmental disease group, and includes: a memory 12 for storing operation information showing an operation by an evaluation object person A, the operation being for a virtual space in which a task is set, displayed in a user terminal 3; and an arithmetic part 11 for evaluating an execution function of the evaluation object person. An index of the execution function of the evaluation object person is calculated using relationships among a plurality of virtual spaces of the operation information by the evaluation object person in each of the plurality of virtual spaces with different set tasks, displayed in the user terminal.SELECTED DRAWING: Figure 1

The invention relates to the field of neurodevelopmental disorders, and discloses an electro-oculogram signal analysis and diagnosis system based on neurodevelopmental disorders, which extracts signal features from pre-processed electro-oculogram signals, and analyzes inter-group differences between signal features of a child patient group and signal features of a healthy child group. The method comprises the following steps: preliminarily screening out signal features with significant statistical difference between two groups, then carrying out severity correlation analysis on the screened signal features, screening and forming a feature list highly related to ADHD severity, and then comparing eye movement features of a child patient group under natural behaviors with eye movement features of a healthy child group, so as to obtain a feature list related to ADHD severity. The method comprises the following steps of: identifying and forming an abnormal signal feature list, fusing the feature list highly related to the ADHD severity and the abnormal signal feature list, calculating a comprehensive abnormal score, drawing an ROC curve according to the calculated comprehensive abnormal score, and carrying out grading evaluation on the ADHD severity of a child patient, so that accurate diagnosis and severity judgment on the ADHD disease are realized.

The disclosure provides a method of reducing occurrence of a neurodevelopmental disorder (ND) in a subject at risk for developing an ND, the method comprising administering a composition comprising an equol-producing bacterium or gut-health-promoting bacterium to the subject.

The present invention relates to a composition for treating or preventing neurodevelopmental disorders, particularly autism spectrum disorder, by selectively activating brain-resident regulatory T cells (Tregs). The present composition comprises IL-2 or an IL-2 gene (AAV-GFAP-IL-2) as an active ingredient, and induces Treg proliferation in the brain to alleviate neuroinflammation and improve behavioral defects.

The present invention relates to compounds of formula (Ia) and their pharmaceutical composition These compounds are for the use in the treatment of a disease or disorder selected from the group consisting of fungal infections, bacterial infections, neurological and neurodevelopmental disorders and cancer.

The invention discloses a method for constructing a neurodevelopmental disorder animal model based on central nervous system myelin sheath function change and application, and belongs to the technical field of biological engineering. An Msl2 gene conditional knockout mouse model is constructed by adopting a gene engineering technology, the space-time specific knockout of a second exon of the Msl2 gene in a specific cell type is realized through a Cre-LoxP recombinase system, and the exon encodes a key enzyme activity region for catalyzing ubiquitination. Model construction is based on central nervous system oligodendrocyte / myelin sheath dysfunction, the behavior phenotype of the model is similar to the behavior of a typical neurodevelopment disorder animal, a brand new perspective is provided for exploring an etiology mechanism, model mice can be prepared on a large scale by performing directional mating on the gene modified mice, and the development of the model is promoted. And consistency of different experiment batches and reliable reproduction of experiment data are ensured.

Methods of treating neurodevelopmental disorders by administering an acetylated amino acid having a carbon-nitrogen bond and acetyl group covalently bound to the nitrogen of the carbonnitrogen bond and having a three-dimensional structure that allows the acetylated amino acid to enter cells and neurons are described. In one embodiment, the acetylated amino acid is a compound of Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 is each independently H or D, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the acetylated amino acid are also described.

Methods of treating a neurodevelopmental disorder caused by a mutation in HNRNPH2 or PCDH19, comprising downregulating expression of HNRNPH2 or PCDH19 in cells of the brain of a subject are provided. Antisense oligonucleotides useful in performing the methods of the invention are also provided.

Aspects of the present disclosure relate to expression cassettes encoding miniShank3 proteins, AAV vectors containing the expression cassettes, and gene therapy methods, particularly where the expression cassettes are formulated to further contain an AAV9 capsid, and the gene therapy is useful for treating neurodevelopmental disorders such as autism spectrum disorder (ASD) and Phelan-McDermid syndrome.

To provide a composition of trophinetide. [Solution] This disclosure describes a compound of formula (I), its stereoisomers, by-compounds, pharmaceutical compositions, and methods for producing such compounds using silylating agents, as well as methods for producing compositions and products produced using such methods. More specifically, this disclosure describes the production of trophinetides and by-products, compositions, and products containing such compounds for pharmaceutical applications for the treatment of neurodegenerative or neurodevelopmental disorders. JPEG2026063085000110.jpg55147

Described herein are antisense oligonucleotides (ASOs), vectors, and related compositions and methods for increasing endogenous expression of SHANK3 protein, and uses thereof in disorders associated with SHANK3 haploinsufficiency, such as Phelan-McDermid Syndrome.

The invention relates to therapeutic compositions for disorders associated with haploinsufficiency. The invention provides antisense oligonucleotides useful for treating neurodevelopmental disorders associated with mutations in the SYNGAP gene. The invention provides compositions that include synthetic antisense oligonucleotides (ASOs) that promote expression of the SynGAP protein by one or any combination of (i) preventing one or more miRNAs from interfering with production of the SynGAP protein; (ii) binding to 5′-UTR of the SYNGAP1 transcript and augmenting translation of the Syngap protein; and (iii) promoting RNAseH cleavage of antisense long non-coding RNAs that are anticorrelated with SYNGAP expression. When the composition is delivered to a patient with SYNGAP haploinsufficiency, the ASOs promote expression of the SynGAP protein.

Disclosed herein are systems for modifying nucleic acid splicing of a target RNA such as a SCN2A mRNA. The system may be useful in a method such as a method for treating a neurodevelopmental disorder. The system may include an expression system, or a modified small nuclear RNA (snRNA) that includes an exonic splicing silencer (ESS) sequence, and a target nucleic acid sequence that targets the target RNA.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

The invention discloses a method for constructing a social anomaly mouse model, relates to the technical field of animal model construction, and constructs a social anomaly model of a filial generation mouse by performing bisphenol S exposure on a female mouse in a pregnancy and nursing period. According to the mouse model constructed by the invention, in the pregnancy and nursing period, BPS is exposed, and the development of left secondary motor cortex neurons is damaged, so that progeny is induced to have social behavior disorder; the activity of neurons in the left M2 brain region is activated, so that social behavior disorders can be effectively relieved. The invention not only clarifies the neural development mechanism of the environmental endocrine disrupter-induced autism-like social disorder, but also provides a new thought of activating left M2 neurons as a potential intervention means, and can be used for developing drugs for treating the social behavior disorder induced by the environmental endocrine disrupter; the invention provides a new direction for etiological research and treatment strategy exploration of neurodevelopment disorder diseases taking social defects as core symptoms, and is beneficial to promoting deep development of related medical research.

This invention discloses a method for calculating a polygenic risk score (PRS or PRS score) for predicting autism and neurodevelopmental disorders (hereinafter collectively referred to as diseases). Its key feature is the improvement in the accuracy of predicting the relative risk of potential diseases by incorporating the genetic effects of rare variants (MAF < 0.1%) and common variants (MAF > 0.1%). This invention uses loss-of-function (LoF) rare variants detected by DNA sequencing (including but not limited to NGS / 3GS) to calculate gene-based PRS scores; and integrates these scores into existing snp-based PRS scores based solely on common variants detected by GWAS; thereby solving the problem of low variance interpretation (pseudo-R) in snp-based PRS scores calculated only based on common variants. 2 (and the problem of low predictive ability.)

A therapeutic composition is provided which comprises at least one agent which specifically interferes with PTBP2-binding in the SYNGAP1 gene region to prevent dysfunctional protein production caused by an alternative splicing event, which dysfunctional protein is associated with a disease or disorder. The agent can be an anti-sense oligonucleotide, an RNAi, or combinations thereof. The composition may further comprise a pharmaceutically acceptable aqueous diluent suitable for intrathecal injection. Also provided are methods of treating SYNGAP1-related neurodegenerative disorders.

Methods of treatment of neurodevelopmental disorders via administration of organic tricyclic compounds are described. Organic tricyclic compounds administered in the method of the invention include nortriptyline, amitriptyline and their pharmaceutically acceptable salts. Pharmaceutical compositions and dosage forms containing organic tricyclic compounds are also described.